SATURN shows plaque statin benefit

Statins have revolutionized the treatment of cardiovascular disease and have repeatedly demonstrated their ability to reduce adverse cardiovascular outcomes.  However despite tantalizing data from some trials suggesting statins may even be capable of causing disease regression, few studies have formally assessed the comparative ability of competing drugs to achieve this. […]

Read More…

AIM-HIGH fails to fly

Despite the efficacy of statins in reducing the risk of cardiovascular disease a substantial number of patients go on to have further events, even when LDL cholesterol targets are achieved.  Consequently, interest has grown in combination therapy approaches and the HDL raising treatment niacin – a drug now over 50 years old – has enjoyed […]

Read More…

Clinical Trials in CPR

Out-of-hospital cardiac arrest is a common and lethal problem, with an estimated 330,000 deaths each year in North America alone. Even in those cases where help arrives in a timely fashion, outcomes remain dismal with estimates of survival to hospital discharge ranging from 3.0% to 16.3%.  Compounding the situation is the difficulty associated with conducting […]

Read More…

Ambulatory BP Monitoring Cost-Effective

Affecting a billion people, hypertension is the cardiovascular risk factor associated with the highest mortality worldwide. There are well-documented problems in the detection of hypertension, as it varies throughout the day and in response to various stimuli. Out-of-office options have been developed that monitor blood pressure either at home or whilst ambulatory, and have been […]

Read More…

Cardiac biomarkers and prognosis in COPD

Cardiovascular disease is common in patients with COPD with the two conditions often being linked by the common aetiology of smoking.  Moreover, dysfunction in one organ system can transmit to the other with severe hypoxemia, pulmonary hypertension, and systemic inflammation all potentially impacting on cardiac function.  However, the interplay between lung and cardiac disease is […]

Read More…

When good cholesterol turns bad

Increasing levels of circulating HDL (“good cholesterol”) has been targeted as an important therapeutic goal in reducing the risk of patients with coronary disease.  HDL has been shown to have a variety of potentially beneficial effects including cholesterol efflux from foam cells, promotion of endothelial repair mechanisms and stimulation of the enzyme eNOS to increase […]

Read More…

Chronic NSAID use increases mortality from cardiovascular disease

Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective and extensively used pain-killers, particularly in the treatment of chronic musculoskeletal problems.  However, doubts about their safety in patients with coronary disease have surfaced, particularly since the NSAID-like COX1 inhibitor, rofecoxib, was withdrawn from the market after a demonstrated  increase in cardiovascular events.  Despite these concerns, compelling data on […]

Read More…